Arrowhead Pharmaceuticals, Inc. (ARWR)
The company now
Arrowhead reported revenue of $75.3 million for the quarter ended 30 June 2026, up from $27.8 million a year earlier 2.
Partner payments drove it: $26.4 million from Sarepta, $20.2 million from Novartis and $25.0 million from Madrigal 2.
The operating loss for the quarter was $170.1 million, as research and development spending reached $198.2 million 2.
The company's first approved medicine, REDEMPLO, won FDA approval on 18 November 2025 for familial chylomicronemia syndrome, a rare disease 1.
Two Phase 3 studies of the same medicine in severe hypertriglyceridemia, a higher blood fat condition, met their main goal, the company said 2.
As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed. Nothing here is advice.
Newer filings are on file since this was written; an update is queued.
Where the revenue comes from
No split of its revenue is on file yet.
The desk's written account, in full. As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed. Nothing here is advice.
Past
Arrowhead develops medicines that silence disease-causing genes, using RNA interference, a natural process in cells that switches off one chosen gene 1.
Its revenue has swung with partner payments: it was $240.7 million in fiscal 2023, then fell to $3.6 million in fiscal 2024 1.
Fiscal 2024 ended with an operating loss of $601.1 million 1.
Research and development spending rose from $505.9 million that year to $607.2 million in fiscal 2025 1.
Most of that rise came from candidate costs, which grew as more drug candidates moved into and through clinical trials, the company said 1.
On 25 November 2024 the company signed a deal with Sarepta Therapeutics for programs in rare genetic diseases of the muscle, the central nervous system and the lungs 1.
At closing Sarepta bought $325.0 million of new Arrowhead shares and paid a $500.0 million upfront fee 1.
That is why revenue jumped by $825.9 million to $829.4 million in fiscal 2025, mainly from the Sarepta, Sanofi and GSK license agreements 1.
Sarepta alone accounted for $696.8 million of that year's revenue 1.
On 1 August 2025 Visirna, a majority-owned subsidiary, sold its plozasiran rights in Greater China to Sanofi, which added $130.0 million of revenue that year 1.
On 29 August 2025 it also agreed a Novartis deal for ARO-SNCA, a Parkinson's disease program, with $200.0 million upfront and up to $2.0 billion in potential milestones 1.
The partner money turned fiscal 2025 into an operating profit of $98.3 million 1.
Present
REDEMPLO and plozasiran
REDEMPLO is an injection that lowers triglycerides, a type of blood fat, in adults with familial chylomicronemia syndrome 1.
In the PALISADE trial, the 25 mg dose cut triglycerides by a median of 80 percent against 17 percent for placebo 1.
The company reports approvals in China, Canada, Australia and the European Union, with Sanofi marketing it in Greater China 2.
In severe hypertriglyceridemia, SHASTA-3 and SHASTA-4 showed median triglyceride reductions of 79 percent and 81 percent, the company said 2.
Other medicines in trials
The pipeline holds 18 candidates the company discovered, in trials from Phase 1 to Phase 3 1.
Zodasiran, for the rare inherited cholesterol condition homozygous familial hypercholesterolemia, finished enrolling its Phase 3 YOSEMITE trial, with 70 patients 2.
ARO-INHBE and ARO-ALK7, aimed at obesity, are in Phase 1/2a trials 2.
ARO-MAPT, for tauopathies including Alzheimer's disease, has begun a Phase 1/2a trial 2.
Partners and licensed programs
Programs the company does not plan to sell itself are licensed to partners including Sarepta, Amgen, Takeda, GSK and Novartis 1.
On 4 May 2026 it licensed ARO-PNPLA3, a liver disease program, to Madrigal Pharmaceuticals for a $25 million upfront payment and up to $975 million in milestones 2.
Places and people
The headquarters are in Pasadena, California, with labs in San Diego and Madison, Wisconsin 1.
The company owns land in Verona, Wisconsin, with a drug manufacturing building of about 160,000 square feet 1.
It employed 711 full-time employees on 30 September 2025, and Christopher Anzalone is president and chief executive 1.
The umbrella, in words
The annual report names five subsidiaries: Arrowhead Madison, Arrowhead Australia, Arrowhead New Zealand, Arrowhead Ireland and Visirna Therapeutics 1.
Visirna is majority owned by the company 1.
In a contract, Royalty Pharma agreed in November 2022 to pay up to $410.0 million for a future royalty interest in olpasiran, which Amgen licenses 1.
Future
The company said it plans to file a supplemental application with the FDA for severe hypertriglyceridemia in 2026, pending successful completion of its Phase 3 studies 1.
It anticipates that YOSEMITE will be completed in mid-2027 and, pending successful results, intends to seek approval in multiple regions after that 2.
Under the Novartis deal it is eligible for up to $2.0 billion in milestone payments, plus royalties on sales 1.
The company expects to make $40.0 million of prepayments on its secured term loan within the next 12 months 1.
What it may be looking into
No clue on file points to a new direction yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
The desk has not written this company's report yet.
Sources
a number beside a sentence opens its entry in its own document's listThe written account 2 sources · as of Oct 28, 2026
- Form 10-K, annual report for the fiscal year ended 30 September 2025 ↗Arrowhead Pharmaceuticals, Inc. (SEC filing) · filed Nov 25, 2025
- Form 10-Q, quarterly report for the quarter ended 30 June 2026 ↗Arrowhead Pharmaceuticals, Inc. (SEC filing) · filed Aug 4, 2026